Amgen Inc (AMGN): Cost of Revenue
$12.04B
Year ended 2025-12-31
$11.61B
Trailing 12 months to 2026-06-30
+23.4%
3-year compound annual growth
+14.3%
5-year compound annual growth
+11.0%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.04B | -6.4% | 2026-02-13, From 2025-01-01 |
| 2024-12-31 | $12.86B | +52.1% | 2026-02-13, From 2024-01-01 |
| 2023-12-31 | $8.45B | +31.9% | 2026-02-13, From 2023-01-01 |
| 2022-12-31 | $6.41B | -0.7% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $6.45B | +4.8% | 2024-02-14, From 2021-01-01 |
| 2020-12-31 | $6.16B | +41.4% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $4.36B | +6.2% | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $4.10B | +0.8% | 2021-02-09, From 2018-01-01 |
| 2017-12-31 | $4.07B | -2.2% | 2020-02-12, From 2017-01-01 |
| 2016-12-31 | $4.16B | -1.5% | 2019-02-13, From 2016-01-01 |
| 2015-12-31 | $4.23B | -4.4% | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $4.42B | +32.2% | 2017-02-14, From 2014-01-01 |
| 2013-12-31 | $3.35B | +4.6% | 2016-02-16, From 2013-01-01 |
| 2012-12-31 | $3.20B | +18.1% | 2015-02-19, From 2012-01-01 |
| 2011-12-31 | $2.71B | n/a | 2014-02-24, From 2011-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Amgen Inc (AMGN) | 2025-12-31 | $12.04B | -6.4% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $6.23B | -0.3% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.40B | +4.1% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $52.10M | +53.2% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $83.70M | +9.8% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $790.50M | -21.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $868.00M | -40.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $228.77M | +43.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $415.97M | -3.1% |
Compare AMGN, GILD, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗